Individual analyst names with their specific EPS, revenue, R&D, and SG&A estimates broken out in the consensus estimates panel 2.C onsensus estimates panel should include analyst averages for R&D and SG&A line items, not just EPS and revenue — especially critical for biopharma where R&D spend is a primary value driver